BNTX:NASDAQ
BioNTech SE - ADR
$88.08
arrow_downward
-1.69%(-1.51) 1D
$88.75
arrow_upward
+0.76% (+0.67)bedtimeAfter hours
Closed: Jun 5, 4:00:01 PM GMT-4 · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BNTX...
Open
$89.51
High
$89.95
Low
$87.75
Mkt. cap
22.27B
Avg. vol.
896.48K
Volume
837.44K
52-wk high
$123.98
52-wk low
$79.52
EPS
-$5.89
Beta
1.30
Shares outstanding
252.88M
No. of employees
8K
Open
$89.51
High
$89.95
Low
$87.75
Mkt. cap
22.27B
Avg. vol.
896.48K
Volume
837.44K
52-wk high
$123.98
52-wk low
$79.52
EPS
-$5.89
Beta
1.30
Shares outstanding
252.88M
No. of employees
8K
Analyst outlook
Analyst Ratings
Based on 18 analysts giving stock ratings to BNTX in the past 3 months
Strong Buy
Buy
15
Hold
3
Sell
0
12 month forecast
Based on 18 Wall Street analysts offering 12 month price targets for BNTX in the last 3 months.
Highest
Current $88.08
$167.00 (+89.60%)
Average
$131.39 (+49.17%)
Lowest
$94.00 (+6.72%)
News stories
From sources across the web
AD HOC NEWS
·
11 hours ago
BioNTech Stock Under Siege: Technical Breakdown, Reform Jitters, and a Pipeline That Can’t Catch a
Investing.com
·
11 hours ago
Bernstein reiterates BioNTech stock rating on pumitamig risks
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR
AI content may include mistakes. Learn more